A Randomized, double-blind, placebo-controlled, three-way cross-over study to assess the pharmacodynamic effects of an authorised and a new compound on nerve excitability threshold tracking in healthy male subjects.

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-510721-26-00

Acronym

CHDR2371

Enrollment

Registered

2024-05-06

Start date

2024-05-17

Completion date

2024-10-14

Last updated

2024-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

neuropathic pain

None listed

Sex/Gender

Male

Age

18 Years to 64 Years

Netherlands

None listed

Source: EU CTIS · Data processed: Feb 4, 2026